Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30105% above fair value
$14.35+0.14 (+0.99%)
Close on Nov 18, 2026Market cap $38.31MP/E –Yield –
Yarrow Bioscience revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Yarrow Bioscience's revenue for the twelve months ending Jun 30, 2025 was $476.00K, down 2.1% year over year. For fiscal 2025 it was $570.00K, up 13.8% from the year before. The highest annual figure on record is $20.99M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $570.00K | +13.8% |
| FY2024 | Dec 31, 2024 | $501.00K | +18.2% |
| FY2023 | Dec 31, 2023 | $424.00K | -11.1% |
| FY2022 | Dec 31, 2022 | $477.00K | -48.8% |
| FY2021 | Dec 31, 2021 | $931.00K | -95.6% |
| FY2020 | Dec 31, 2020 | $20.99M | +4638.8% |
| FY2019 | Dec 31, 2019 | $443.00K | -87.7% |
| FY2018 | Dec 31, 2018 | $3.60M | -21.5% |
| FY2017 | Dec 31, 2017 | $4.58M | +579.8% |
| FY2016 | Dec 31, 2016 | $674.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $97.00K | +15.5% |
| Q1 FY2026 | Mar 31, 2026 | $86.00K | -28.9% |
| Q2 FY2025 | Jun 30, 2025 | $69.00K | -65.2% |
| Q1 FY2025 | Mar 31, 2025 | $202.00K | +106.1% |
| Q4 FY2024 | Dec 31, 2024 | $84.00K | +10.5% |
| Q3 FY2024 | Sep 30, 2024 | $121.00K | +6.1% |
| Q2 FY2024 | Jun 30, 2024 | $198.00K | +46.7% |
| Q1 FY2024 | Mar 31, 2024 | $98.00K | -1.0% |
| Q4 FY2023 | Dec 31, 2023 | $76.00K | +1166.7% |
| Q3 FY2023 | Sep 30, 2023 | $114.00K | -31.7% |
| Q2 FY2023 | Jun 30, 2023 | $135.00K | +7.1% |
| Q1 FY2023 | Mar 31, 2023 | $99.00K | -44.4% |
| Q4 FY2022 | Dec 31, 2022 | $6.00K | -97.8% |
| Q3 FY2022 | Sep 30, 2022 | $167.00K | +25.6% |
| Q2 FY2022 | Jun 30, 2022 | $126.00K | -57.3% |
| Q1 FY2022 | Mar 31, 2022 | $178.00K | -22.6% |
| Q4 FY2021 | Dec 31, 2021 | $273.00K | -93.6% |
| Q3 FY2021 | Sep 30, 2021 | $133.00K | -95.9% |
| Q2 FY2021 | Jun 30, 2021 | $295.00K | -97.5% |
| Q1 FY2021 | Mar 31, 2021 | $230.00K | -86.9% |
| Q4 FY2020 | Dec 31, 2020 | $4.29M | +3074.8% |
| Q3 FY2020 | Sep 30, 2020 | $3.27M | – |
| Q2 FY2020 | Jun 30, 2020 | $11.69M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.75M | +468.2% |
| Q4 FY2019 | Dec 31, 2019 | $135.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $308.00K | -38.0% |
| Q4 FY2018 | Dec 31, 2018 | $0 | -100.0% |
| Q3 FY2018 | Sep 30, 2018 | $0 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | $10.14M | +2159.0% |
| Q1 FY2018 | Mar 31, 2018 | $497.00K | +10.7% |
| Q4 FY2017 | Dec 31, 2017 | $2.78M | – |
| Q3 FY2017 | Sep 30, 2017 | $909.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $449.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $449.00K | – |
See a number that looks wrong?